Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)2.04bn
- Net income in SEK547.78m
- Incorporated2004
- Employees265.00
- LocationCamurus ABRydbergs torg 4LUND 224 84SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioGaia AB | 1.42bn | 309.74m | 10.29bn | 224.00 | 34.10 | 5.94 | 31.15 | 7.25 | 3.06 | 3.06 | 14.04 | 17.59 | 0.629 | -- | -- | 6,307,498.00 | 13.73 | 14.76 | 14.90 | 16.03 | 72.81 | 73.06 | 21.83 | 27.38 | -- | -- | 0.00 | 129.54 | 9.73 | 13.11 | -3.82 | 13.40 | -18.36 | 33.95 |
| Bonesupport Holding AB | 997.85m | 122.34m | 18.65bn | 140.00 | 153.47 | 25.52 | 140.41 | 18.69 | 1.85 | 1.85 | 15.01 | 11.10 | 1.23 | 0.6421 | 6.11 | 7,857,103.00 | 15.05 | 5.14 | 18.36 | 6.31 | 92.60 | 91.40 | 12.26 | 5.59 | 3.47 | 17.65 | 0.0168 | 0.00 | 52.05 | 42.04 | -45.41 | -- | 5.71 | -- |
| Bavarian Nordic A/S | 9.29bn | 1.97bn | 19.91bn | 1.65k | 10.22 | 1.14 | 6.70 | 2.14 | 16.57 | 16.57 | 78.33 | 148.46 | 0.4586 | 1.41 | 6.75 | 3,867,985.00 | 9.72 | 3.31 | 11.78 | 4.02 | 51.90 | 52.68 | 21.20 | 9.80 | 1.44 | -- | 0.01 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| Vimian Group AB | 4.34bn | 214.04m | 20.44bn | 1.20k | 96.27 | 2.70 | 33.53 | 4.71 | 0.4099 | 0.4099 | 8.32 | 14.60 | 0.375 | 1.76 | 6.48 | 3,612,990.00 | 1.96 | -- | 2.20 | -- | 69.01 | -- | 5.23 | -- | 1.22 | 4.87 | 0.2423 | -- | 12.95 | -- | 88.01 | -- | -- | -- |
| Camurus AB | 2.04bn | 547.78m | 36.24bn | 265.00 | 66.33 | 10.26 | 64.20 | 17.80 | 9.16 | 9.16 | 34.07 | 59.22 | 0.5792 | 1.09 | 5.02 | 7,952,883.00 | 15.58 | 8.65 | 17.44 | 10.46 | 93.23 | 91.31 | 26.91 | 12.01 | 9.10 | -- | 0.0297 | 0.00 | 8.78 | 77.63 | -0.7065 | -- | 1.29 | -- |
| ALK-Abello A/S | 8.51bn | 1.40bn | 55.96bn | 2.74k | 43.33 | 7.23 | 30.92 | 6.58 | 4.28 | 4.28 | 26.08 | 25.62 | 0.7625 | 1.26 | 6.44 | 2,073,375.00 | 12.52 | 6.01 | 15.29 | 7.60 | 64.45 | 61.95 | 16.42 | 8.44 | 0.9875 | 57.35 | 0.1235 | 0.00 | 14.78 | 11.08 | 67.70 | -- | 50.82 | -- |
| Orion Oyj | 17.67bn | 3.87bn | 99.38bn | 3.94k | 25.66 | 8.35 | 22.62 | 5.63 | 2.47 | 2.47 | 11.29 | 7.58 | 1.00 | 1.52 | 6.24 | 409,407.20 | 21.96 | 20.14 | 28.93 | 24.67 | 61.54 | 59.72 | 21.86 | 21.16 | 2.27 | 125.29 | 0.2314 | 84.25 | 29.65 | 7.97 | 52.17 | 10.48 | 19.14 | 1.80 |
| Swedish Orphan Biovitrum AB (publ) | 26.24bn | 3.96bn | 101.32bn | 1.90k | 24.93 | 2.50 | 13.19 | 3.86 | 11.41 | 11.41 | 75.72 | 113.64 | 0.3628 | 1.53 | 4.90 | 14,258,700.00 | 5.47 | 5.23 | 6.84 | 6.70 | 78.30 | 77.70 | 15.07 | 15.19 | 0.6547 | 5.05 | 0.2643 | 0.00 | 17.65 | 12.81 | 61.27 | 3.29 | -20.97 | -- |
Data as of Jun 30 2025. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
20.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Apr 2025 | 2.81m | 4.77% |
| Swedbank Robur Fonder ABas of 30 May 2025 | 2.50m | 4.25% |
| Handelsbanken Fonder ABas of 31 May 2025 | 1.32m | 2.25% |
| The Vanguard Group, Inc.as of 04 Jun 2025 | 1.18m | 2.00% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 1.09m | 1.85% |
| AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 30 Apr 2025 | 783.69k | 1.33% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 700.35k | 1.19% |
| SEB Investment Management ABas of 30 May 2025 | 677.83k | 1.15% |
| Baillie Gifford & Co.as of 31 May 2025 | 641.31k | 1.09% |
| Devon Equity Management Ltd.as of 31 May 2025 | 633.52k | 1.08% |
More ▼
Data from 31 Dec 2024 - 10 Jun 2025Source: FactSet Research Systems Inc.
